Cambrex Executive and Leadership Team

Thomas Loewald, the Chief Executive Officer at Cambrex, directs the company's overarching strategy and global operations. Loewald guides Cambrex's mission to provide comprehensive drug substance, drug product, and analytical services, leveraging over 40 years of experience. This leadership role involves ensuring the company's continued growth and market leadership in both branded and generic pharmaceutical sectors. Loewald oversees the integration of specialized drug substance technologies, including continuous flow and highly potent APIs, with conventional and specialty dosage form manufacturing. By fostering innovation and operational excellence, Thomas Loewald drives the company's commitment to being a trusted partner for clients across North America and Europe, ultimately advancing the drug lifecycle from development through commercialization.

Robert Green, the Executive VP & Chief Financial Officer at Cambrex, directs the company's financial strategy and fiscal operations. Green manages all aspects of financial planning, analysis, and reporting, ensuring the economic health and sustainable growth of Cambrex's global operations. This executive oversees capital allocation, investment strategies, and financial risk management, supporting the company's extensive service offerings in drug substance, drug product, and analytical services. Robert Green plays a critical role in funding the expansion of specialized drug substance technologies and manufacturing capabilities across North America and Europe. By maintaining robust financial discipline, Green enables Cambrex to continue serving as a premier partner for clients in the branded and generic pharmaceutical markets, underpinning the company's long-term success.

Richard Lifsitz, the Chief Operating Officer at Cambrex, executes the company's operational strategies across its global network. Lifsitz manages the day-to-day functions essential for delivering drug substance, drug product, and analytical services, ensuring efficiency and quality throughout the drug lifecycle. This executive oversees the integration of advanced manufacturing capabilities, such as continuous flow and solid-state science, with the production of conventional and specialty dosage forms. Richard Lifsitz is responsible for optimizing supply chains and manufacturing processes to meet the demands of clients in the branded and generic markets. By driving operational excellence, Lifsitz ensures Cambrex maintains its reputation as a reliable partner, supporting the development and manufacturing of APIs and finished dosage forms from North America to Europe.

Bruno Biscaro, the President, Drug Products at Cambrex, leads the strategic direction and operational execution for all drug product development and manufacturing. Biscaro oversees the comprehensive capabilities in conventional and specialty dosage forms, including oral solids, semi-solids, liquids, and advanced forms like modified-release and bi-layer tablets. This leadership role ensures the seamless integration of drug product services with drug substance and analytical support, providing end-to-end solutions across the drug lifecycle. Bruno Biscaro drives innovation in manufacturing technologies and quality systems to meet the stringent demands of branded and generic pharmaceutical clients globally. By focusing on operational excellence and client collaboration, Biscaro solidifies Cambrex's position as a trusted partner for bringing critical medicines to market from its North American and European facilities.

Dottie Brienza, the Chief Human Resources Officer at Cambrex, architects the company's talent strategy and cultivates its expert workforce. Brienza oversees all human capital initiatives, ensuring Cambrex attracts, develops, and retains the specialized professionals required for drug substance, drug product, and analytical services. This leadership position focuses on fostering a culture of innovation and collaboration that supports the company's 40-year legacy and its global client base across North America and Europe. Dottie Brienza drives programs that enhance employee engagement and professional growth, aligning human resources with the company's strategic objectives in both branded and generic pharmaceutical markets. By prioritizing people, Brienza ensures the team's expertise directly contributes to Cambrex's success as a trusted partner in drug development and manufacturing.